caa a22 4500 605491453 CHVBK 20210128100510.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10147-015-0798-3 doi (NATIONALLICENCE)springer-10.1007/s10147-015-0798-3 Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay [Elektronische Daten] [Hye-young Wang, Sungwoo Ahn, Sunghyun Kim, Sunyoung Park, Dongju Jung, Sangjung Park, Hyunju Han, JooHyuk Sohn, SeungIl Kim, Hyeyoung Lee] Background: Breast cancer is a highly prevalent disease among women worldwide. While the expression of certain proteins within breast cancer tumors is used to determine the prognosis and select therapies, additional markers need to be identified. Circulating tumor cells (CTCs) are constituent cells that have detached from a primary tumor to circulate in the bloodstream. CTCs are considered the main source of breast cancer metastases; therefore, detection of CTCs could be a promising diagnostic method for metastatic breast cancer. Methods: In this study, the CircleGen CTC RT-qDx assay was used to analyze the mRNA expression levels of six CTC-specific markers including EpCAM, CK19, HER2, Ki67, hTERT, and vimentin with a total of 692 peripheral whole blood samples from 221 breast cancer patients and 376 healthy individuals. Results: This assay showed high specificity with multiple markers; none of the healthy controls were detected positive, whereas 21.7 and 14% of breast cancer patients were positive for EpCAM and CK19, respectively. Of the 221 breast cancer patients, 84 (38%), 46 (20.8%), 83 (37.6%), and 39 (17.6%) were positively for HER2, Ki67, hTERT, and vimentin mRNA, respectively. Of the 84 patients who were HER2 positive, nine (4%) were also positive for EpCAM, CK19, Ki67, hTERT, and vimentin. Of the 139 breast cancer patients who were HER2 negative, 65 (29.1%) were negative for EpCAM, CK19, Ki67, hTERT, and vimentin. Furthermore, the EpCAM-positive population decreased from 21.5 to 8.3% after completion of anti-tumor treatment (TP4). Similarly, the CK19, HER2, hTERT, and vimentin positives also decreased from 13.9 to 9.5%, from 37.7 to 21.4%, from 37.2 to 33.3%, and from 17.5 to 14.3%, respectively, after completion of anti-tumor treatment. In contrast, the Ki67 positives increased from 20.6 to 41.7% after completion of anti-tumor treatment. Conclusions: mRNA overexpression of six CTC-specific markers was detected by the CircleGen CTC RT-qDx assay with high specificity, and the obtained mRNA expression levels of CTC-specific markers might provide useful criteria to select appropriate anti-tumor treatment for breast cancer patients. Japan Society of Clinical Oncology, 2015 Circulating tumor cells (CTCs) nationallicence Breast cancer nationallicence RT-qPCR nationallicence Anti-tumor treatment nationallicence Molecular diagnosis nationallicence Wang Hye-young M&D, Inc., Wonju Eco Environmental Technology Center, Wonju, Gangwon, Republic of Korea aut Ahn Sungwoo Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, 1 Yonseidae-gil, 220-710, Wonju, Gangwon, Republic of Korea aut Kim Sunghyun Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, 1 Yonseidae-gil, 220-710, Wonju, Gangwon, Republic of Korea aut Park Sunyoung Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, 1 Yonseidae-gil, 220-710, Wonju, Gangwon, Republic of Korea aut Jung Dongju Department of Biomedical Laboratory Science, College of Natural Sciences, Hoseo University, Chungnam, Republic of Korea aut Park Sangjung Department of Clinical Laboratory Science, College of Medical Science, Daegu Haany University, Daegu, Republic of Korea aut Han Hyunju Avison Biomedical Research Center, Yonsei University Medical Center, Seoul, Republic of Korea aut Sohn JooHyuk Division of Medical Oncology, Severance Breast Cancer Clinic, Yonsei Cancer Center, Seoul, Republic of Korea aut Kim SeungIl Department of Surgery, Yonsei University College of Medicine, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, 120-752, Seoul, Republic of Korea aut Lee Hyeyoung Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, 1 Yonseidae-gil, 220-710, Wonju, Gangwon, Republic of Korea aut International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 878-890 1341-9625 20:5<878 2015 20 10147 https://doi.org/10.1007/s10147-015-0798-3 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0798-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wang Hye-young M&D, Inc., Wonju Eco Environmental Technology Center, Wonju, Gangwon, Republic of Korea aut NATIONALLICENCE 700 1- Ahn Sungwoo Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, 1 Yonseidae-gil, 220-710, Wonju, Gangwon, Republic of Korea aut NATIONALLICENCE 700 1- Kim Sunghyun Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, 1 Yonseidae-gil, 220-710, Wonju, Gangwon, Republic of Korea aut NATIONALLICENCE 700 1- Park Sunyoung Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, 1 Yonseidae-gil, 220-710, Wonju, Gangwon, Republic of Korea aut NATIONALLICENCE 700 1- Jung Dongju Department of Biomedical Laboratory Science, College of Natural Sciences, Hoseo University, Chungnam, Republic of Korea aut NATIONALLICENCE 700 1- Park Sangjung Department of Clinical Laboratory Science, College of Medical Science, Daegu Haany University, Daegu, Republic of Korea aut NATIONALLICENCE 700 1- Han Hyunju Avison Biomedical Research Center, Yonsei University Medical Center, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Sohn JooHyuk Division of Medical Oncology, Severance Breast Cancer Clinic, Yonsei Cancer Center, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Kim SeungIl Department of Surgery, Yonsei University College of Medicine, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, 120-752, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Lee Hyeyoung Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, 1 Yonseidae-gil, 220-710, Wonju, Gangwon, Republic of Korea aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 878-890 1341-9625 20:5<878 2015 20 10147